PubMed:21300721 / 124-796 JSONTXT

{"project":"PubMed_Structured_Abstracts","denotations":[{"id":"T1","span":{"begin":0,"end":672},"obj":"OBJECTIVE"}],"text":"The level of inhibition of the human Ether-à-go-go-related gene (hERG) channel is one of the earliest preclinical markers used to predict the risk of a compound causing Torsade-de-Pointes (TdP) arrhythmias. While avoiding the use of drugs with maximum therapeutic concentrations within 30-fold of their hERG inhibitory concentration 50% (IC(50)) values has been suggested, there are drugs that are exceptions to this rule: hERG inhibitors that do not cause TdP, and drugs that can cause TdP but are not strong hERG inhibitors. In this study, we investigate whether a simulated evaluation of multi-channel effects could be used to improve this early prediction of TdP risk."}

{"project":"PubmedHPO","denotations":[{"id":"T1","span":{"begin":169,"end":187},"obj":"HP_0001664"},{"id":"T2","span":{"begin":194,"end":205},"obj":"HP_0011675"}],"text":"The level of inhibition of the human Ether-à-go-go-related gene (hERG) channel is one of the earliest preclinical markers used to predict the risk of a compound causing Torsade-de-Pointes (TdP) arrhythmias. While avoiding the use of drugs with maximum therapeutic concentrations within 30-fold of their hERG inhibitory concentration 50% (IC(50)) values has been suggested, there are drugs that are exceptions to this rule: hERG inhibitors that do not cause TdP, and drugs that can cause TdP but are not strong hERG inhibitors. In this study, we investigate whether a simulated evaluation of multi-channel effects could be used to improve this early prediction of TdP risk."}

{"project":"Allie","denotations":[{"id":"SS1_21300721_2_0","span":{"begin":31,"end":63},"obj":"expanded"},{"id":"SS2_21300721_2_0","span":{"begin":65,"end":69},"obj":"abbr"},{"id":"SS1_21300721_2_1","span":{"begin":169,"end":187},"obj":"expanded"},{"id":"SS2_21300721_2_1","span":{"begin":189,"end":192},"obj":"abbr"}],"relations":[{"id":"AE1_21300721_2_0","pred":"abbreviatedTo","subj":"SS1_21300721_2_0","obj":"SS2_21300721_2_0"},{"id":"AE1_21300721_2_1","pred":"abbreviatedTo","subj":"SS1_21300721_2_1","obj":"SS2_21300721_2_1"}],"text":"The level of inhibition of the human Ether-à-go-go-related gene (hERG) channel is one of the earliest preclinical markers used to predict the risk of a compound causing Torsade-de-Pointes (TdP) arrhythmias. While avoiding the use of drugs with maximum therapeutic concentrations within 30-fold of their hERG inhibitory concentration 50% (IC(50)) values has been suggested, there are drugs that are exceptions to this rule: hERG inhibitors that do not cause TdP, and drugs that can cause TdP but are not strong hERG inhibitors. In this study, we investigate whether a simulated evaluation of multi-channel effects could be used to improve this early prediction of TdP risk."}